

Achieved 243.1% of the Enrollment Goal in a Phase 2b Obesity Trial

Our Objectives

DelRicht Research was selected as a participating site network for a Phase 2b trial targeting adults living with overweight or obesity. The trial aimed to recruit adults aged 18 years or older, with at least one comorbidity.

- **Study Enrollment Goal:** 872 patients across 65 sites
- **DelRicht's Enrollment Goal:** 93.8 patients across 7 sites
- **Patient Population:** Adults ≥18 years old
- **Enrollment Period:** May 2026 – August 2026 (3 months)

Activation to Screening Timeline



Key Trial Challenges & Solutions

CHALLENGES

Key trial challenges included: **1) Eligibility criteria** requiring verification of sustained weight stability, comorbidities, diabetes exclusions, and medication washouts; and **2) Patient burden** involving dual injections, long frequent visits, fasting labs, 24-hr Holter monitoring, ongoing safety tracking, and side-effect management.



HOW DELRICHT ADDRESSED

Sites supported trial success through: **1) Identifying qualified patients via referral networks & prescreened records** to streamline recruitment; and **2) Dedicated coordinators, proactive side-effect education, automated ePRO reminders, & consolidated visit assessments** to minimize patient burden and ensure quality data capture.

The Study

Client: Large Biopharma

Trial: U.S. Phase 2b Obesity Trial

Participating PIs

Dr. Jennifer Zomnir | Dallas, TX

Dr. Kymberly Moyer | Hendersonville, TN

Dr. Luke Van Kirk | Springfield, MO

Dr. Olabisi Badmus | Charlotte, NC

Dr. Rachael Murphy | Mandeville, LA

Dr. Taylor Sanders | Prairieville, LA

Dr. Vijayendra Jaligam | Vienna, VA

Our Results

DelRicht's seven sites achieved a rapid **2.6-day average activation to screening** timeline. In addition, our network **enrolled 228 patients, 243.1% of the expected enrollment goal**. This performance demonstrates rapid site screening, coordinated execution, and consistent ability to deliver high-quality data and dependable outcomes for sponsors.

 **2.6 Days** Avg. Activation to Screening

 **228** Patients Enrolled

 **243.1%** of the Expected Enrollment Goal